Alpha Teknova, Inc.: financial statements

TKNONASDAQHealthcare · In Vitro & In Vivo Diagnostic Substances

Price

$7.85

November 16, 2026Market cap $494M

What Ploutos Investor adds for Alpha Teknova

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+5.1% a year over 2 years

Line202320242025Average a year
Revenue $37M$38M$41M+5.1%
Cost of revenue $26M$31M$27M+1.3%
Gross profit $10M$7.2M$13M+14.2%
Operating income -$36M-$26M-$17M
Net income -$37M-$27M-$17M
Earnings per share -$1.16-$0.57-$0.32
Earnings per share, basic -$1.16-$0.57-$0.32
Margins
Gross margin 28.1%19.2%33.2%
Operating margin -96.9%-69.3%-41.9%
Net margin -100.3%-70.9%-42.6%

Financial statements

TKNO's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: Lab Essentials $29M, Clinical Solutions $6.7M, Other Product $1.1M
  • 2024: Lab Essentials $29M, Clinical Solutions $7.1M, Other Product $1.8M
  • 2025: Lab Essentials $31M, Clinical Solutions $7.7M, Other Product $1.8M
Product202320242025Share 2025
Lab Essentials$29M$29M$31M77%
Clinical Solutions$6.7M$7.1M$7.7M19%
Other Product$1.1M$1.8M$1.8M4.5%

By segment

TKNO's revenue by product line from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 5 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$0 Due within 2 years$15M Leases-0.3% Effective tax rate

When the debt falls due

Dec 31, 2025

Due within 2 years

$0

Principal of loans and bonds falling due, from the annual report dated December 31, 2025, without leases and interest. The filing

  • 2026: $0
  • 2027: $0

Leases

Dec 31, 2025

Operating leases

$15M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

-0.3%

-21.3 pts

The company paid -0.3% in tax on its profit, 21.3 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-20.7 pts

Difference the filing does not itemize

-0.6 pts

Effective rate

-0.3%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Sep 30, 2026, sales were +21.5% on the same quarter a year earlier, and receivables +13.3%. Inventory was +8.1%, against +8.7% for the cost of sales.

a year earlier 45 days
42 days
a year earlier 87 days
86 days

Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Allowance for doubtful accounts

The allowance for receivables that may not be collected was 0.5% of gross receivables at Sep 30, 2026, against 0.9% a year earlier.

At last year's share it would be $24.2K larger. A smaller allowance means a smaller charge for bad debts in profit.

a year earlier $48.0K
$30.0K

Taxes: deferred and paid

The deferred part was 87.9% of the tax charge in the year to Dec 31, 2025.

Cash taxes paid were 28.6% of the current tax charge in the year to Dec 31, 2025.

  • The deferred share is higher than at nine in ten S&P 500 companies.
  • Cash taxes paid against the current charge are lower than at nine in ten S&P 500 companies.
Deferred share, year to Dec 31, 2025$51.0K of $58.0K
87.9%
$2.0K paid, $7.0K current
28.6%

When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do Alpha Teknova's filings show?

These are Alpha Teknova's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about TKNO's financials

Didn't find what you were looking for?

Ask us
How much revenue did TKNO have in 2025?

Alpha Teknova had revenue of $41M and net income of -$17M in fiscal 2025, a net margin of -42.6%.

How much debt does TKNO have?

On December 31, 2025 Alpha Teknova had total assets of $104M, debt of $13M and shareholders' equity of $69M.

How much free cash flow does TKNO have?

In fiscal 2025 Alpha Teknova had cash from operations of -$8.6M and spent $1.1M on capital expenditure, leaving -$9.8M of free cash flow.

Where are the figures from?

From Alpha Teknova, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.